This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess

This study is not yet open for participant recruitment.
See Contacts and Locations
Verified December 2016 by Christine Burt Solorzano, University of Virginia
Sponsor:
Information provided by (Responsible Party):
Christine Burt Solorzano, University of Virginia
ClinicalTrials.gov Identifier:
NCT01422707
First received: August 19, 2011
Last updated: December 16, 2016
Last verified: December 2016
  Purpose
Short term hydrocortisone to test whether improves excess androgen production from adrenal gland and ovaries

Condition Intervention
Hyperandrogenemia Obesity Polycystic Ovary Syndrome Drug: Hydrocortisone

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS003)

Resource links provided by NLM:


Further study details as provided by Christine Burt Solorzano, University of Virginia:

Primary Outcome Measures:
  • Changes in free testosterone after ACTH administration before and after hydrocortisone administration for 4 weeks [ Time Frame: 30 and 60 minutes after ACTH, baseline, and after 4 weeks of hydrocortisone administration ]

Secondary Outcome Measures:
  • Changes in adrenal steroid precursors after ACTH, baseline, and after 4 weeks of hydrocortisone administration [ Time Frame: 30 and 60 minutes after ACTH, baseline, and after 4 weeks of hydrocortisone administration ]

Estimated Enrollment: 20
Study Start Date: April 2017
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: hydrocortisone
4 weeks hydrocortisone with pre- and post-intervention Dexamethasone and Cosyntropin to perform standardized adrenal stimulation testing
Drug: Hydrocortisone
10 mg/m2/per day PO at bedtime (X4 weeks)
Other Name: Cortef

Detailed Description:
This study will test whether short-term suppression of adrenal function can ameliorate androgen (male hormone) overproduction in overweight girls with androgen excess. The investigators hypothesize that one month of oral hydrocortisone administration will improve androgen levels in girls with adrenal androgen overproduction. Specifically, this intervention will improve androgen levels after adrenal stimulation testing with adrenocorticotropin hormone (ACTH).
  Eligibility

Ages Eligible for Study:   7 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Overweight(>85th BMI%) females
  • Early to late puberty (expected age range 7-18)
  • Hyperandrogenemic (free testosterone greater than 2.5 standard deviations above the mean for normal control subjects of the same Tanner Stage)
  • Screening labs within age-appropriate normal range, with the exception of a mildly low hematocrit (see below) and the hormonal abnormalities inherent in obesity which could include mildly elevated luteinizing hormone (LH), lipids, testosterone, prolactin, DHEAS, E2, glucose, and insulin; and decreased follicle-stimulating hormone (FSH) and/or sex hormone-binding globulin (SHBG)

Exclusion Criteria:

  • Screening labs outside of age-appropriate normal range
  • Hemoglobin <12 mg/dL and hematocrit<36% (Subjects will be offered the opportunity to take iron supplementation for 60 days if their hematocrit is slightly low (33-36%) (suggestive of iron deficiency anemia) and will then return for retesting of their hemoglobin/hematocrit. If still <36%, they will be excluded.)
  • Morning Cortisol <5 g/dL
  • 17-hydroxyprogesterone >295 ng/dL
  • History of Cushing's syndrome or adrenal insufficiency
  • Pregnant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01422707

Contacts
Contact: Deborah Sanderson 434-243-6911 pcos@virginia.edu
Contact: Christine M. Burt Solorzano, MD 434-243-6911 pcos@virginia.edu

Locations
United States, Virginia
University of Virginia Center for Research in Reproduction Not yet recruiting
Charlottesville, Virginia, United States, 22908
Contact: Deborah Sanderson    434-243-6911    pcos@virginia.edu   
Contact: Christine M. Burt Solorzano, MD    434-243-6911    pcos@virginia.edu   
Principal Investigator: Christine M. Burt Solorzano, MD         
Sub-Investigator: John C. Marshall, MD, PhD         
Sponsors and Collaborators
University of Virginia
Investigators
Principal Investigator: Christine M. Burt Solorzano, MD University of Virginia
  More Information

Responsible Party: Christine Burt Solorzano, Assistant Professor of Pediatrics, University of Virginia
ClinicalTrials.gov Identifier: NCT01422707     History of Changes
Other Study ID Numbers: CBS003
CBS003 ( Other Identifier: University of Virginia )
Study First Received: August 19, 2011
Last Updated: December 16, 2016

Additional relevant MeSH terms:
Ovarian Cysts
Overweight
Polycystic Ovary Syndrome
Hyperandrogenism
Body Weight
Signs and Symptoms
Cysts
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases
46, XX Disorders of Sex Development
Disorders of Sex Development
Urogenital Abnormalities
Adrenogenital Syndrome
Congenital Abnormalities
Epinephrine
Racepinephrine
Epinephryl borate
Hydrocortisone 17-butyrate 21-propionate
Cortisol succinate
Hydrocortisone acetate
Hydrocortisone
Androgens
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents

ClinicalTrials.gov processed this record on June 23, 2017